A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT07711418

Public ClinicalTrials.gov record NCT07711418. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

Study identification

NCT ID: NCT07711418
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Nektar Therapeutics; Industry
Enrollment: 510 participants

Conditions and interventions

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

Rezpegaldesleukin Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 7, 2026 (Actual)
Primary completion: Jun 2028 (Estimated)
Completion: Jan 2029 (Estimated)
Last update posted: Sep 8, 2026

2026 – 2029

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Nektar Investigative Site	Birmingham	Alabama	35203	Recruiting
Nektar Investigative Site	Oxnard	California	93030	Recruiting
Nektar Investigative Site	Palmdale	California	93551	Recruiting
Nektar Investigative Site	Sacramento	California	95815	Recruiting
Nektar Investigative Site	Tamarac	Florida	33321	Recruiting
Nektar Investigative Site	Savannah	Georgia	31406	Recruiting
Nektar Investigative Site	Metairie	Louisiana	70006	Recruiting
Nektar Investigative Site	Kirksville	Missouri	63501	Recruiting
Nektar Investigative Site	Lee's Summit	Missouri	64064	Recruiting
Nektar Investigative Site	Las Vegas	Nevada	89144	Recruiting
Nektar Investigative Site	Robbinsville	New Jersey	08691	Recruiting
Nektar Investigative Site	The Bronx	New York	10455	Recruiting
Nektar Investigative Site	Columbus	Ohio	43213	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07711418, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 8, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07711418 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →